Sign In
Buy ACON
$3.49
-0.0100 (-0.286%)
At Close: Jun 03, 2026
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
06:00am, Wednesday, 03'rd Jun 2026
Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
06:04am, Monday, 01'st Jun 2026
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain.
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
06:00am, Monday, 01'st Jun 2026
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain Nociscan's underlying MRS technology enabled measurement of intradisca
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
03:04pm, Thursday, 28'th May 2026
BROOMFIELD, Colo., May 28, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
02:49pm, Thursday, 28'th May 2026
BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and propr
Echo Lake Capital Offers To Acquire Aclarion Inc.
08:00am, Thursday, 28'th May 2026
Offers $4.00 per share in cash plus CVR Stock currently trades below the value of its cash and other assets Believes company's public shell worth at least another $6 million if Board effected a revers
Aclarion (ACON) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 19'th May 2026
Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
07:11pm, Wednesday, 13'th May 2026
Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $9.32 per share a year ago.
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
04:51pm, Monday, 11'th May 2026
“Matching the right procedure to the right patient is what moves the field forward” BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
06:00am, Thursday, 07'th May 2026
“Matching the right procedure to the right patient is what moves the field forward” Lanman Spinal Neurosurgery is a leading spine-focused private practice recognized for its expertise in complex s
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
06:04am, Wednesday, 06'th May 2026
Expansion of the commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., May 06, 2026 – PRISM MediaWire (Press Release Service –
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
06:00am, Wednesday, 06'th May 2026
BROOMFIELD, Colo., May 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging bio
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
06:03am, Tuesday, 05'th May 2026
Broomfield, CO, May 05, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-st
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
06:00am, Tuesday, 05'th May 2026
BROOMFIELD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging b
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
06:05am, Thursday, 30'th Apr 2026
Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows.
